Myriad Genetics reiterated at strong buy by JMP

JMP Securities analyst Charles C. Duncan reiterated Myriad Genetics, Inc. at a strong buy and a $33 price target on news that the company's fourth-quarter 2006 financial results show strong Predictive Medicine (PM) sales growth. Myriad's results met the analyst's and consensus revenues and net loss estimates with solid growth in PM revenue. JMP projected PM revenue of $30.1 million for the quarter, slightly above the reported $28.8 million. Shares of the Salt Lake City-based biopharmaceutical company were down $1.56, or 5.90%, at $24.90, on volume of 745,852 shares versus the three-month running average of 316,369 shares. (Nasdaq: MYGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.